Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib in Combination With Anti-HER2 Therapies in Advanced HER2+ Breast Cancer
NCT02390427Phase 1Completed
- Sponsor
- Nancy Lin
- Start
- Apr 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taselisib / pictilisib in breast cancer (4 arms), sponsored by Nancy Lin. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2015; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02390427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390427.